The global abetalipoproteinemia management market is expected to surpass an impressive valuation of US$ 147 million in 2023 and is projected to reach US$ 341 million by 2033, growing at a CAGR of 8.78 %.
Rising prevalence of imaging studies like hepatic scans or ultrasonography to assess changes in fatty liver, Magnetic resonance imaging (MRI) of the spinocerebellar region which may show degeneration will drive the market of Abetalipoproteinemia during the forecast period.
Increasing incidences of inborn metabolic disorders due to changing lifestyles of a child’s parents are likely to propel market growth. However, the high cost of treatment and dearth of awareness will restrain market expansion.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 147 million |
| Anticipated Forecast Value (2033) | US$ 341 million |
| Projected Growth Rate (2023 to 2033) | CAGR 8.78 % |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market of Abetalipoproteinemia grossed a valuation of US$ 110 million in 2018 while growing at a CAGR of 5.97 %. The growth is attributable to various factors including high-dose vitamin supplementation, which is the mainstay for treatment and may prevent, delay, or alleviate the complications and improve the prognosis, enabling some patients to live to the eighth decade of life.
The diagnostic criteria and entry criterion of low-density lipoprotein cholesterol (LDL-C) 15 mg/dL and apoB 15 mg/dL can be useful in universal or opportunistic screening for Abetalipoproteinemia. Registry research on Abetalipoproteinemia is currently ongoing to better understand the disease burden and unmet needs of this life-threatening disease with few therapeutic options.
Other mainstays of treatment include adherence to a low-fat diet and supplementation with essential fatty acids. Prognosis is variable, but early diagnosis and strict adherence to treatment can recover normal neurological function and halt disease progression which will lead to market expansion in the forecast period. Considering these factors and developments, FMI has estimated the market of Abetalipoproteinemia to garner a valuation of US$ 341 million with a CAGR of 8.78 % by end of the forecast period.
Technological Advancements fuelling the Market Expansion
Growth in the well-structured diagnostic treatment facility will uplift the market growth, also a rise in the research and development activities in the market, Rise in the healthcare expenditures, and increasing demand from emerging economies are some of the crucial factors among others propelling abetalipoproteinemia treatment market growth.
Moreover, the rise in technological advancements and modernization in healthcare machinery and growth in demand from emerging economies will further open up new avenues for the abetalipoproteinemia treatment market in the forecast period of 2023 to 2033. Along with this, the growing demand for one-time therapies against inborn metabolic disorders is likely to serve as a revenue generator in the Abetalipoproteinemia diagnostics market.
Principal Consultant
High Cost of Diagnostic Tests likely to stymie Uptake
There have been several tests that are immensely available for testing inborn metabolic disorders like Abetalipoproteinemia. But these tests are of a growing cost that is not affordable for several patients, mostly belonging to the lower economic groups. Therefore, it restrains market growth.
North America dominating the Market with Highest Market Share
This region is expected to dominate the market with a 39% market share while exhibiting a CAGR of 7.5% by end of the forecast period. A superior healthcare system and advancement in research & development in the field are propelling market growth in the region.
Moreover, high healthcare expenditure and rising awareness about inborn metabolic disorders are anticipated to drive the regional market further.
South Asia to reflect the fastest growth in the Forecast Period
The abetalipoproteinemia management market in this region will witness the fastest CAGR of 8% during the forecast period. The market is projected to be worth around US$ 110 million by end of the forecast period. China will lead the market with an estimated valuation of US$ 65 million, growing at a CAGR of 8.9% during the forecast period.
The growth is attributable to rapid economic development, rising demand for molecular genetic testing, and hypercholesterolemia diseases, along with increased disposable income levels are propelling growth in this region. Moreover, rising cases of malnutrition in these regions will also aid in market expansion.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Blood Testing Treatment to possess Highest Market Share
The blood testing treatment market is expected to dominate the market with a segment share of 61.7% by end of the forecast period. Rising adoption of blood tests to detect low levels of both lipids, such as cholesterol and triglycerides, and lipid-soluble vitamins such as A, E, and K to diagnose Abetalipoproteinemia will augment this segment’s growth.
Hospitals and clinics dominate the market with substantial market revenue
Hospitals & clinics are projected to lead the market with a contribution of around 71% during the forecast period. Increasing investment by industry players in Research and development activities is augmenting the segment’s growth. Furthermore, the rapid adoption of new novel therapies and drugs in hospitals is also leading to market expansion.
The market is fragmented and moderately competitive. The strategies like mergers and acquisitions adopted by major market players will boost the market growth. The major players in the market are Lonza, Piramal Pharma Solutions, Abbott Laboratories, Koninklijke DSM N.V., Barrington Nutritionals, Ion Labs Inc, Galderma Laboratories, Johnson & Johnson Services, Inc, Medimetriks Pharmaceuticals, Inc., and F-Hoffmann-La Roche.
Some Recent Developments in this industry are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 147 million |
| Market Value in 2033 | US$ 341 million |
| Growth Rate | CAGR of 8.78% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
Japan may witness significant growth in the abetalipoproteinemia management market.
New product launches and government initiatives drive sales of abetalipoproteinemia management.
Technological advancements and rising prevalence of the disease.
The market grossed a valuation of US$ 110 million in 2018 while growing at a CAGR of 5.97 %.
Substantial investment in research and development, marketing and sales.
1. Executive Summary | Abetalipoproteinemia Management Market
1.1. Global Market Outlook
1.2. Demand to side Trends
1.3. Supply to side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y to o to Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Molecular Genetic Testing Treatment
5.3.2. Blood Testing Treatment
5.3.2.1. Fat to Soluble Vitamins Supplementation
5.3.2.2. Others
5.4. Y to o to Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End to user
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End to the user, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End to the user, 2023 to 2033
6.3.1. Hospitals & Clinics
6.3.2. Diagnostics Lab
6.3.3. Others
6.4. Y to o to Y Growth Trend Analysis By End to the user, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End to the user, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia
7.3.5. East Asia
7.3.6. Oceania
7.3.7. Middle East & Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End to user
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End to user
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End to user
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End to user
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End to user
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End to user
10.4. Key Takeaways
11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Rest of South Asia
11.2.2. By Treatment
11.2.3. By End to user
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End to user
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Treatment
12.2.3. By End to user
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End to user
12.4. Key Takeaways
13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Treatment
13.2.3. By End to user
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment
13.3.3. By End to user
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Treatment
14.2.3. By End to user
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment
14.3.3. By End to user
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Treatment
15.1.2.2. By End to user
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Treatment
15.2.2.2. By End to user
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Treatment
15.3.2.2. By End to user
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Treatment
15.4.2.2. By End to user
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Treatment
15.5.2.2. By End to user
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Treatment
15.6.2.2. By End to user
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Treatment
15.7.2.2. By End to user
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Treatment
15.8.2.2. By End to user
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Treatment
15.9.2.2. By End to user
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Treatment
15.10.2.2. By End to user
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Treatment
15.11.2.2. By End to user
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Treatment
15.12.2.2. By End to user
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Treatment
15.13.2.2. By End to user
15.14. China
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Treatment
15.14.2.2. By End to user
15.15. Japan
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Treatment
15.15.2.2. By End to user
15.16. South Korea
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Treatment
15.16.2.2. By End to user
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Treatment
15.17.2.2. By End to user
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Treatment
15.18.2.2. By End to user
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Treatment
15.19.2.2. By End to user
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Treatment
15.20.2.2. By End to user
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Treatment
15.21.2.2. By End to user
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment
16.3.3. By End to user
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Lonza
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Piramal Pharma Solutions
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Abbott Laboratories
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Koninklijke DSM N.V.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Barrington Nutritionals
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Ion Labs Inc.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Galderma Laboratories
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Johnson & Johnson Services, Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Medimetriks Pharmaceuticals, Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. F to Hoffmann to La Roche
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Abetalipoproteinemia Management Market
